Cypre's blog to discuss the latest movements in science.
Cypre’s CEO, Kolin Hribar, was interviewed by the CRL Eureka blog on the future of oncology drug development, and how 3D models will play a central role in determining the next set of cancer immunotherapies.
Partner with Cypre to generate translational insights using our 3D tumor microenvironment organoid platform. From targeting the tumor or stroma, to modulating the immune system, we’re built for collaboration.
